August 13, 2018

Genentech Clinical Trial for Treatment of Wet Age-Related Macular Degeneration (AMD) Shows Promising Results

Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)

At Wolfe Eye Clinic, we are extremely excited to share the Phase II LADDER Study results that were released in late July by Genentech. As people with Wet AMD may need as often as monthly eye injections with the current standard of care, the LADDER study is investigating a port delivery system intended to reduce the burden of frequent eye injections by allowing people to go several months before needing a refill of the implant. The LADDER study is investigating a port delivery system using ranibizumab (Lucentis) from Genentech.

The first-ever eye implant is a small, refillable device, slightly longer than a grain of rice, that is uniquely designed to continuously deliver ranibizumab over time.  The majority of study patients went six months or longer between the implant of the device and the first required refill, which mirrored the results achieved by our study patient with the implanted device in Des Moines.  We look forward to moving into Phase III of the trial, which is expected to begin later in 2018. View the full press release here.

f you wish to discuss these results, or any of the other retina studies Wolfe Eye Clinic is currently taking part in, please contact Dr. Jared Nielsen, Director of Retina Clinical Trial, at jnielsen@wolfeclinic.com.